ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that its Analyst & Investor Day for research analysts and institutional investors will take place on Friday, October 19 at 8:00 a.m. (ET) in New York City. Harvey J. Berger, M.D., chairman and chief executive officer of ARIAD, will host the event, which will include other key members of ARIAD executive leadership. The meeting will focus on ARIAD’s commercial plans for ponatinib and continued progress in its research and development programs. An expert physician specializing in the treatment of patients with lung cancer will be a featured speaker and discussant at the meeting.
A live webcast of the Analyst & Investor Day can be accessed by visiting the investor relations section of ARIAD’s website at http://www.ariad.com/investor. A replay of this investor event will be available on the ARIAD website approximately three hours after the presentation and will be archived for three weeks.
ARIAD Pharmaceuticals, Inc. is an emerging global oncology company focused on the discovery, development and commercialization of medicines to transform the lives of cancer patients. ARIAD’s approach to structure-based drug design has led to several internally discovered, molecularly targeted product candidates for drug-resistant or difficult-to-treat cancers, including certain forms of chronic myeloid leukemia and non-small cell lung cancer. For additional information, visit http://www.ariad.com or follow ARIAD on Twitter (@ARIADPharm).